As of 2026-04-09, the EV/EBITDA ratio of Pliant Therapeutics Inc (PLRX) is -0.16. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PLRX's latest enterprise value is 35.66 mil USD. PLRX's TTM EBITDA according to its financial statements is -219.95 mil USD. Dividing these 2 quantities gives us the above PLRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2026-04-08 | -0.18 |
| 2026-04-07 | -0.16 |
| 2026-04-06 | -0.16 |
| 2026-04-02 | -0.17 |
| 2026-04-01 | -0.16 |
| 2026-03-31 | -0.15 |
| 2026-03-30 | -0.12 |
| 2026-03-27 | -0.12 |
| 2026-03-26 | -0.14 |
| 2026-03-25 | -0.16 |
| 2026-03-24 | -0.15 |
| 2026-03-23 | -0.16 |
| 2026-03-20 | -0.16 |
| 2026-03-19 | -0.17 |
| 2026-03-18 | -0.15 |
| 2026-03-17 | -0.17 |
| 2026-03-16 | -0.16 |
| 2026-03-13 | -0.17 |
| 2026-03-12 | -0.19 |
| 2026-03-11 | -0.17 |
| 2026-03-10 | -0.18 |
| 2026-03-09 | -0.16 |
| 2026-03-06 | -0.17 |
| 2026-03-05 | -0.16 |
| 2026-03-04 | -0.16 |
| 2026-03-03 | -0.15 |
| 2026-03-02 | -0.15 |
| 2026-02-27 | -0.16 |
| 2026-02-26 | -0.16 |
| 2026-02-25 | -0.15 |
| 2026-02-24 | -0.15 |
| 2026-02-23 | -0.14 |
| 2026-02-20 | -0.14 |
| 2026-02-19 | -0.16 |
| 2026-02-18 | -0.15 |
| 2026-02-17 | -0.11 |
| 2026-02-13 | -0.11 |
| 2026-02-12 | -0.11 |
| 2026-02-11 | -0.12 |
| 2026-02-10 | -0.12 |
| 2026-02-09 | -0.12 |
| 2026-02-06 | -0.11 |
| 2026-02-05 | -0.10 |
| 2026-02-04 | -0.12 |
| 2026-02-03 | -0.13 |
| 2026-02-02 | -0.13 |
| 2026-01-30 | -0.13 |
| 2026-01-29 | -0.14 |
| 2026-01-28 | -0.15 |
| 2026-01-27 | -0.15 |